Immunexpress Showcases SeptiCyte RAPID® at 2026 SCCM Congress in Chicago

Immunexpress at the 2026 Society of Critical Care Medicine Congress

Immunexpress, a leading molecular diagnostics company specializing in sepsis outcomes, made waves at the Society of Critical Care Medicine (SCCM) 2026 Critical Care Congress held in Chicago from March 22-24, 2026. With a strong focus on enhancing patient diagnosis and management for suspected cases of sepsis, Immunexpress presented its innovative SeptiCyte RAPID® test, which has garnered significant attention for its precision and rapid results.

On March 22, Dr. Roy Davis, the Chief Medical Officer, delivered a compelling presentation during the Research Snapshot Theatre, centered on the poster titled "Determining the Likelihood of Blood Culture Positivity in Sepsis in One Hour Using SeptiCyte RAPID." This session highlighted the test's capability to provide vital diagnostic results promptly, an essential factor in the management of sepsis, which is often life-threatening if not addressed swiftly.

In addition to the presentation, Immunexpress hosted booth #642 throughout the congress, showcasing two recent publications that detail the clinical applications and robust performance of the SeptiCyte RAPID® test. This device is designed to distinguish between sepsis and non-infectious systemic inflammation in patients, which can be particularly challenging in septic cases.

The Power of SeptiCyte RAPID®

The SeptiCyte RAPID® test employs advanced reverse transcription polymerase chain reaction (RT-PCR) technology to analyze whole blood. By quantifying the expression of two crucial host response genes, PLAC8 and PLA2G7, it generates a SeptiScore® in around one hour. This score helps healthcare practitioners quickly assess the likelihood of sepsis, facilitating timely therapeutic interventions.

The effectiveness of the SeptiCyte RAPID® test has been illustrated through several studies. One notable study involved hematological malignancy patients with neutropenic fever, where the test demonstrated a strong diagnostic performance, achieving an AUC of 0.84. This highlights its reliability in distinguishing infectious cases from non-infectious fevers, turning out to be critical in compromised patient populations.

Another critical aspect of the findings revealed that SeptiCyte RAPID® correlated well with blood culture positive sepsis cases, showing an impressive 91% alignment. Moreover, it identified sepsis cases that were adjudicated as blood culture negative at a rate of 77%. With an AUC of 0.91 for differentiating between infectious and non-infectious systemic inflammation, the implications are profound for patient management.

Dr. Davis emphasized the test's role in enhancing diagnostic precision which, in turn, supports earlier decisions regarding antimicrobial treatments. This advancement minimizes the unnecessary use of antibiotics and promotes better stewardship practices, especially vital for high-risk groups, including patients who have undergone bone marrow transplants and have neutropenia.

Why This Matters

The rapid turnaround time of the SeptiCyte RAPID® test is particularly significant, with results available 12 to 24 hours ahead of traditional blood cultures. This early insight allows healthcare teams to make informed decisions without delay, ultimately improving outcomes for patients in critical settings.

Immunexpress is committed to pushing the boundaries of sepsis diagnostics further. With a dedicated base in Brisbane, Australia, and Seattle, USA, they strive to provide innovative solutions that not only improve patient outcomes but also reduce the financial strain of sepsis on healthcare systems globally.

The 2026 SCCM Congress showcased not just the capabilities of SeptiCyte RAPID® but also the potential of modern diagnostics to transform patient care in critical settings. As Immunexpress continues to innovate, the future of sepsis management looks increasingly promising, embodying a significant advancement in medical science and patient health outcomes.

For ongoing updates and more information about Immunexpress and its technologies, visit their official website and follow them on professional networks like LinkedIn.